Przedstawiamy wybór publikacji naukowych związanych z immunoterapią IOZK. Możesz użyć filtrów, aby dokonać wyboru według typów nowotworów i metod lub wprowadzić wyszukiwane hasła.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-08-01 / Int J Hyperthermia 2008 Aug;24(5):399-408https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-08-01 / Int J Hyperthermia 2008 Aug;24(5):399-4082008-08-01 00:00:002008-08-01 00:00:00Regional hyperthermia of the abdomen in conjunction with chemotherapy for peritoneal carcinomatosis: evaluation of two annular-phased-array applicators
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-08-01 / J Biomech Eng 2008 Aug;130(4):041016https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-08-01 / J Biomech Eng 2008 Aug;130(4):0410162008-08-01 00:00:002019-02-15 10:00:35A two-state cell damage model under hyperthermic conditions: theory and in vitro experiments
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-08-01 / Clin. Cancer Res. 2008 Aug;14(15):4850-8https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-08-01 / Clin. Cancer Res. 2008 Aug;14(15):4850-82008-08-01 00:00:002008-08-01 00:00:00A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-07-29 / Cancer Immunol. Immunother. 2008 Nov;57(11):1705-10https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-07-29 / Cancer Immunol. Immunother. 2008 Nov;57(11):1705-102008-07-29 00:00:002019-02-15 08:37:25Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-07-22 / Zhonghua Yi Xue Za Zhi 2008 Jul;88(28):1956-60https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-07-22 / Zhonghua Yi Xue Za Zhi 2008 Jul;88(28):1956-602008-07-22 00:00:002019-02-15 09:23:40[Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-07-11 / Cancer Immunol. Immunother. 2009 Mar;58(3):361-71https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-07-11 / Cancer Immunol. Immunother. 2009 Mar;58(3):361-712008-07-11 00:00:002008-07-11 00:00:00TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-07-10 / J. Viral Hepat. 2008 Nov;15(11):782-9https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-07-10 / J. Viral Hepat. 2008 Nov;15(11):782-92008-07-10 00:00:002019-02-15 08:37:35Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-07-09 / Vaccine 2008 Aug;26(36):4716-24https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-07-09 / Vaccine 2008 Aug;26(36):4716-242008-07-09 00:00:002023-03-07 13:11:25Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-07-01 / Int J Immunopathol Pharmacol 2008 Jul-Sep;21(3):493-500https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-07-01 / Int J Immunopathol Pharmacol 2008 Jul-Sep;21(3):493-5002008-07-01 00:00:002019-02-15 09:19:20Strategies to overcome obstacles to successful immunotherapy of melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-51https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-512008-07-01 00:00:002019-02-15 09:19:24Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-41https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-412008-07-01 00:00:002019-02-15 09:19:25Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):555-62https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):555-622008-07-01 00:00:002019-02-15 09:19:26IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):591-8https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):591-82008-07-01 00:00:002019-02-15 09:19:26Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-07-01 / J. Immunol. 2008 Jul;181(1):808-21https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-07-01 / J. Immunol. 2008 Jul;181(1):808-212008-07-01 00:00:002008-07-01 00:00:00Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells
Dendritic cell vaccines in metastasized malignant melanoma
Regional hyperthermia of the abdomen in conjunction with chemotherapy for peritoneal carcinomatosis: evaluation of two annular-phased-array applicators
A two-state cell damage model under hyperthermic conditions: theory and in vitro experiments
A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas
Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia
[Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide]
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis
Inoperable Pancoast tumors treated with hyperthermia-inclusive multimodality therapies
Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C)
Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
Maximizing dendritic cell migration in cancer immunotherapy
Strategies to overcome obstacles to successful immunotherapy of melanoma
Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma
Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma
Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer
CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo
Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells